TICKERNERD
Menu
MLYSMLYSHealthcare · Biotechnology

MLYS Stock Forecast: Mineralys Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$21
+1.75% on the day

The 11 Wall Street analysts covering Mineralys Therapeutics, Inc. hold a median 12-month price target of $52 — +142.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 21 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.9B
Ticker Nerd rank
19/ 100
Median analyst target
$52
Analysts covering
11
Revenue$0.0
Operating income−$246.0M
Net income−$241.1M
Free cash flow−$32.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.8%
1M
−27.0%
YTD
−40.8%
1Y
−48.9%
From 52W high
−54.6%
From 52W low
+5.8%
$20
$47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MLYS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mineralys Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
19/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
63
Value
54
Accruals
53
Quality
47
Size
36
Momentum
34
Revisions
31
Growth
26
Issuance
8

Volatility (63): The share price has been relatively steady.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MLYS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MLYS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26MLYSHigh $56Median $52Low $29

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $29Median $52High $56

The green dot is the last close — the median target sits +142.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Oct 2026HC Wainwright & Co.ReiteratesBuy$56
12 Oct 2026UBSInitiatesNeutral$29
27 Apr 2026TD CowenInitiatesBuy—
27 Apr 2026TD CowenInitiatesBuy—
13 Mar 2026B of A SecuritiesMaintainsBuy—
19 Dec 2025StifelMaintainsBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025Wells FargoMaintainsOverweight—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
11 Sept 2025Wells FargoMaintainsOverweight—
9 Sept 2025Goldman SachsMaintainsBuy—
8 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025JefferiesMaintainsHold—
28 Aug 2025B of A SecuritiesMaintainsBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025HC Wainwright & Co.ReiteratesBuy—
11 June 2025JefferiesInitiatesHold—
13 May 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025HC Wainwright & Co.MaintainsBuy—
10 Mar 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MLYS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

MLYS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Mineralys Therapeutics, Inc. returned −48.9% against +15.6% for the S&P 500, dividends included.

MLYS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26MLYSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MLYS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
7
Fundamentals

Mineralys Therapeutics, Inc. (MLYS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.3×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
3.4×

Cheaper than 27% of US stocks

EV / EBITDA
−3.6×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−80.9%

Higher than 16% of US stocks

Return on assets
−46.2%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Mineralys Therapeutics, Inc. (MLYS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Mineralys Therapeutics, Inc. has a market value of $1.9B and an enterprise value of $1.3B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$349.6M.

  • Diluted earnings per share, trailing twelve months: $−4.24.

  • Free cash flow in the twelve months to 30 June 2026: −$138.8M.

  • Shares outstanding: 88.4M.

  • Trailing P/E: −9.3×; forward P/E: −8.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Mineralys Therapeutics, Inc. employs 76 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Oct 2026

Data provided by Twelve Data

Peers

MLYS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MLYSMineralys Therapeutics, Inc.$1.9B19
XNCRXencor, Inc.$1.9B79
ADRXADARx Pharmaceuticals, Inc.$1.8B1
BRVEBraveheart Bio, Inc.$1.9B0
SEPNSepterna, Inc.$1.8B88
NVAXNovavax, Inc.$1.8B63
TRVITrevi Therapeutics, Inc.$1.8B49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Mineralys Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MLYS news & analysis

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

GlobeNewsWire · 22 Oct 2026positive

Mineralys Therapeutics presented new data at ASN Kidney Week 2026 showing that lorundrostat achieved similar significant blood pressure reductions in participants with and without chronic kidney disease in the Phase 3 Launch-HTN trial. Reductions were consistent across CKD Stages 1–3.

Why it matters — The findings provide MLYS watchers with information on lorundrostat’s blood pressure effects among trial participants with varying CKD status.

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

GlobeNewsWire · 9 Oct 2026positive

Mineralys Therapeutics presented new analyses from the pivotal Launch-HTN trial at the American Heart Association Hypertension Scientific Sessions 2026. The analyses showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target.

Why it matters — The reported target-achievement result provides MLYS watchers with new clinical-trial data on lorundrostat.

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

GlobeNewsWire · 2 Oct 2026positive

Mineralys Therapeutics announced that new data from its Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, to be held October 21-25 in Denver, Colorado. The presentation was announced on October 2, 2026.

Why it matters — Presentation of new lorundrostat data at a major nephrology conference highlights progress in the company's lead hypertension program and increases visibility among the medical community.

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

GlobeNewsWire · 1 Oct 2026positive

Mineralys Therapeutics announced that five abstracts will be presented at the American Heart Association Hypertension Scientific Sessions 2026, scheduled for October 7-11 in Arlington, VA. The presentations will feature data on lorundrostat, the company's drug candidate for hypertension and aldosterone-related conditions.

Why it matters — MLYS watchers would follow this as it provides a forum for new data on lorundrostat, a key pipeline candidate, at a major hypertension conference.

FAQ

Frequently asked questions about MLYS stock

What is the MLYS stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Mineralys Therapeutics, Inc. have a median 12-month price target of $52, with estimates ranging from $29 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MLYS stock a buy right now?

Of the 11 analysts covering Mineralys Therapeutics, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mineralys Therapeutics, Inc. 19 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MLYS?

As at 21 Oct 2026, Mineralys Therapeutics, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (63 of 100).

Will MLYS stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +142.2% from the last close, and Ticker Nerd's factor model ranks Mineralys Therapeutics, Inc. 19 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MLYS stock forecast for 2030?

No analyst covering Mineralys Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $29 to $56 over the next 12 months.

How has MLYS stock performed over the past year?

Mineralys Therapeutics, Inc. returned -48.9% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mineralys Therapeutics, Inc. do?

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone.

What is the latest news on MLYS?

The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026". Mineralys Therapeutics presented new data at ASN Kidney Week 2026 showing that lorundrostat achieved similar significant blood pressure reductions in participants with and without chronic kidney disease in the Phase 3 Launch-HTN trial. Reductions were consistent across CKD Stages 1–3.

Company

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea. Mineralys Therapeutics concentrates on the treatment of hypertension and related comorbidities, aiming to address patients who do not respond adequately to existing therapies. The company operates as a development-stage drugmaker with a pipeline centered on aldosterone-targeted treatment, combining clinical research, regulatory activity, and outsourced manufacturing and trial operations. Based in Radnor, Pennsylvania, Mineralys Therapeutics plays a specialized role in the biopharmaceutical market by advancing therapies for cardiometabolic and renal diseases with a focus on precision targeting of hormone-driven pathways.

CEO Dr. Jon Congleton · 76 employees · United States · https://mineralystx.com